п??п??п??п??

2 . 2023

Present-day methods of therapeutic angiogenes (literature review)

Abstract

Therapeutic angiogenesis is a trend of treatment based on stimulating the growth of new blood vessels to fill the perfusion deficiency and thereby restore the function of a damaged organ. It is especially important in case of inefficiency or impossibility of surgical methods to re-establish perfusion of ischemic tissues. This method can also be effective at the initial stages of ischemic processes, including for the prevention of disease progression and the development of complications.

Most technologies for stimulating angiogenesis are based on the creation of a high concentration of angiogenic growth factors. Physical and chemical methods can be used to stimulate the production of endogenous proangiogenic molecules. However, the clinical status of patients often implies the presence of defects in the endogenous mechanisms of regulation of angiogenic processes, therefore, the main trend in research is the development of methods for adequate repair of the mechanisms of regulation of angiogenesis. This review presents data on modern technologies of therapeutic angiogenesis, separately considering the state of the art of methods based on therapy with recombinant growth factors, encoding genes, as well as cells and their derivatives, also discussing peculiarities, advantages, and limitations of each of the methods.

Keywords: angiogenesis; therapeutic angiogenesis; growth factor therapy; gene therapy; cellular therapy; stem cell therapy; extracellular vesicles

Funding. The work was carried out within the framework of the state task of the Saratov State Medical University named after V.I. Razumovsky of the Ministry of Health of the Russian Federation "Development of microcameral wound coatings providing local modulation of oxidative tissue homeostasis".

Conflict of interest. The authors declare no conflict of interest.

Authors’ contribution. Study conception and design – Ivanov A.N., Chabbarov Yu.R.; draft manuscript preparation – Ivanov A.N., Chabbarov Yu.R.; manuscript revision – Ivanov A.N., Chabbarov Yu.R.

For citation: Ivanov A.N., Chabbarov Yu.R. Present-day methods of therapeutic angiogenesis (literature review). Аngiology and Vascular Surgery. 2023; 29 (2): 8–20. DOI: https://doi.org/10.33029/1027-6661-2023-29-2-8-20 (in Russian)

References

1. Kosolapov V.P., Yarmonova M.V. The analysis of high cardiovascular morbidity and mortality in the adult population as a medical and social problem and the search for ways to solve it. Ural Medical Journal. 2021; 20 (1): 58–64. DOI: https://doi.org/10.52420/2071-5943-2021-20-1-58-64 (in Russian)

2. Fihn S.D., Gardin J.M., Abrams J., et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. Journal of the American College of Cardiology. 2012; 60: e44–e164. DOI: https://doi.org/10.1016/j.jacc.2012.07.013

3. Conte M.S., Bradbury A.W., Kolh P., et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Journal of Vascular Surgery. 2019; 69 (6S): 3S–125S.e40. DOI: https://doi.org/10.1016/j.jvs.2019.02.016

4. Tien J. Tissue Engineering of the Microvasculature. Comprehensive Physiology. 2019; 9 (3): 1155–1212. DOI: https://doi.org/10.1002/cphy.c180037

5. Edelman E.R., Nugent M.A., Smith L.T., Karnovsky M.J. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. Journal of Clinical Investigation. 1992; 89 (2): 465–473. DOI: https://doi.org/10.1172/JCI115607

6. Laham R.J., Chronos N.A., Pike M., et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. Journal of the American College of Cardiology. 2000; 36 (7): 2132–2139. DOI: https://doi.org/10.1016/s0735-1097(00)00988-8

7. Schumacher B., Pecher P., von Specht B.U., Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation. 1998; 97 (7): 645–650. DOI: https://doi.org/10.1161/01.cir.97.7.645

8. Hendel R.C., Henry T.D., Rocha-Singh K., et al. Effect of Intracoronary Recombinant Human Vascular Endothelial Growth Factor on Myocardial Perfusion: Evidence for a Dose-Dependent Effect. Circulation. 2000; 101 (2): 118–121. DOI: https://doi.org/10.1161/01.CIR.101.2.118

9. Veith A.P., Henderson K., Spencer A., et al. Therapeutic strategies for enhancing angiogenesis in wound healing. Advanced Drug Delivery Reviews. 2019; 146: 97–125. DOI: https://doi.org/10.1016/j.addr.2018.09.010

10. United States Food and Drug Administration, Product Description Regranex, Accessed 3/16/2018.

11. Papanas N., Maltezos E. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Clinical Interventions in Aging. 2008; 3 (2): 233–240. DOI: https://doi.org/10.2147/cia.s1106

12. Singh P., Suresh D.K. Clinical evaluation of GEM 21S(®) and a collagen membrane with a coronally advanced flap as a root coverage procedure in the treatment of gingival recession defects: A comparative study. Journal of Indian Society of Periodontology. 2012; 16 (4): 577–583. DOI: https://doi.org/10.4103/0972-124X.106919

13. Lederman R.J., Mendelsohn F.O., Anderson R.D., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2022; 359 (9323): 2053–2058. DOI: https://doi.org/10.1016/S0140-6736(02)08937-7

14. Simons M., Annex B.H., Laham R.J., et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation. 2002; 105 (7): 788–793. DOI: https://doi.org/10.1161/hc0802.104407

15. Jørgensen K.J., Johansson M. Drawing conclusions from the VIVA trial. Lancet. 2018; 391 (10133): 1894. DOI: https://doi.org/10.1016/S0140-6736(18)30786-4

16. Ucuzian A.A., Gassman A.A., East A.T., Greisler H.P. Molecular Mediators of Angiogenesis. Journal of Burn Care & Research. 2010; 31 (1): 158–175. DOI: https://doi.org/10.1097/BCR.0b013e3181c7ed82

17. Springer M.L., Chen A.S., Kraft P.E., et al. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Molecular Cell. 1998; 2 (5): 549–558. DOI: https://doi.org/10.1016/s1097-2765(00)80154-9

18. Lee R.J., Springer M.L., Blanco-Bose W.E., et al. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation. 2000; 102 (8): 898–901. DOI: https://doi.org/10.1161/01.cir.102.8.898

19. Gianni-Barrera R., Burger M., Wolff T., et al. Long-term safety and stability of angiogenesis induced by balanced single-vector co-expression of PDGF-BB and VEGF164 in skeletal muscle. Scientific Reports. 2016; 6: 21546. DOI: https://doi.org/10.1038/srep21546

20. Ozawa C.R., Banfi A., Glazer N.L., et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. Journal of Clinical Investigation. 2004; 113 (4): 516–527. DOI: https://doi.org/10.1172/JCI18420

21. Sakakibara Y., Tambara K., Sakaguchi G., et al. Toward surgical angiogenesis using slow-released basic fibroblast growth factor. European Journal of Cardio-Thoracic Surgery. 2003; 24 (1): 105–111; discussion 112. DOI: https://doi.org/10.1016/s1010-7940(03)00159-3

22. Kant R.J., Coulombe K.L.K. Integrated approaches to spatiotemporally directing angiogenesis in host and engineered tissues. Acta Biomaterialia. 2018; 69: 42–62. DOI: https://doi.org/10.1016/j.actbio.2018.01.017

23. Ehrbar M., Zeisberger S.M., Raeber G.P., et al. The role of actively released fibrin-conjugated VEGF for VEGF receptor 2 gene activation and the enhancement of angiogenesis. Biomaterials. 2008; 29 (11): 1720–1729. DOI: https://doi.org/10.1016/j.biomaterials.2007.12.002

24. Ku D.D., Zaleski J.K., Liu S., Brock T.A. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. American Journal of Physiology. 1993; 265 (2 Pt 2): H586–592. DOI: https://doi.org/10.1152/ajpheart.1993.265.2.H586

25. Bodnar R.J. Epidermal Growth Factor and Epidermal Growth Factor Receptor: The Yin and Yang in the Treatment of Cutaneous Wounds and Cancer. Advances in Wound Care (New Rochelle). 2013; 2 (1): 24–29. DOI: https://doi.org/10.1089/wound.2011.0326

26. Young L.S., Searle P.F., Onion D., Mautner V. Viral gene therapy strategies: from basic science to clinical application. Journal of Pathology. 2006; 208 (2): 299–318. https://doi.org/10.1002/path.1896

27. Shimatani K., Sato H., Saito A., et al. A novel model of chronic limb ischemia to therapeutically evaluate the angiogenic effects of drug candidates. American Journal of Physiology-Heart and Circulatory Physiology. 2021; 320 (3): H1124–H1135. DOI: https://doi.org/10.1152/ajpheart.00470.2020

28. Rivard A., Fabre J.E., Silver M., et al. Age-dependent impairment of angiogenesis. Circulation. 1999; 99 (1): 111–120. DOI: https://doi.org/10.1161/01.cir.99.1.111

29. Sabra M., Karbasiafshar C., Aboulgheit A., et al. Clinical Application of Novel Therapies for Coronary Angiogenesis: Overview, Challenges, and Prospects. International Journal of Molecular Sciences. 2021; 22 (7): 3722. DOI: https://doi.org/10.3390/ijms22073722

30. Hedman M., Hartikainen J., Syvänne M., et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation. 2003; 107 (21): 2677–2683. DOI: https://doi.org/10.1161/01.CIR.0000070540.80780.92

31. Melillo G., Scoccianti M., Kovesdi I., et al. Gene therapy for collateral vessel development. Cardiovascular Research. 1997; 35 (3): 480–489. DOI: https://doi.org/10.1016/s0008-6363(97)00167-3

32. Kaufmann K.B., Büning H., Galy A., et al. Gene therapy on the move. EMBO Molecular Medicine. 2013; 5 (11): 1642–1661. DOI: https://doi.org/10.1002/emmm.201202287

33. Losordo D.W., Vale P.R., Hendel R.C., et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation. 2002; 105 (17): 2012–2018. DOI: https://doi.org/10.1161/01.cir.0000015982.70785.b7

34. Lavu M., Gundewar S., Lefer D.J. Gene therapy for ischemic heart disease. Journal of Molecular and Cellular Cardiology. 2011; 50 (5): 742–750. DOI: https://doi.org/10.1016/j.yjmcc.2010.06.007

35. Deev R., Plaksa I., Bozo I., Isaev A. Results of an International Postmarketing Surveillance Study of pl-VEGF165 Safety and Efficacy in 210 Patients with Peripheral Arterial Disease. American Journal of Cardiovascular Drugs. 2017; 17 (3): 235–242. DOI: https://doi.org/10.1007/s40256-016-0210-3

36. Shigematsu H., Yasuda K., Iwai T., et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Therapy. 2010; 17 (9): 1152–1161. DOI: https://doi.org/10.1038/gt.2010.51

37. Powell R.J., Goodney P., Mendelsohn F.O., et al. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial. Journal of Vascular Surgery. 2010; 52 (6): 1525–1530. DOI: https://doi.org/10.1016/j.jvs.2010.07.044

38. Komatsuno T. The First Gene Therapy Product in Japan Collategene^® Intramuscular Injection. Digestive Diseases and Sciences. 2019; 34 (4): 305–308. DOI: https://doi.org/10.2745/dds.34.305

39. Banfi A., von Degenfeld G., Blau H.M. Critical role of microenvironmental factors in angiogenesis. Current Atherosclerosis Reports. 2005; 7 (3): 227–234. DOI: https://doi.org/10.1007/s11883-005-0011-7

40. Everts P., Onishi K., Jayaram P., et al. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. International Journal of Molecular Sciences. 2020; 21 (20): 7794. DOI: https://doi.org/10.3390/ijms21207794

41. Ma L., Elliott S.N., Cirino G., et al. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proceedings of the National Academy of Sciences. 2001; 98 (11): 6470–6475. DOI: https://doi.org/10.1073/pnas.111150798

42. Hendow E.K., Day R.M. A facile approach to therapeutic angiogenesis using a platelet concentrate and microsphere composite. Nano Select. 2022; 3: 1042–1047. DOI: https://doi.org/10.1002/nano.202100273

43. Lopez J., Huttala O., Sarkanen J-R., et al. Cytokine-Rich Adipose Tissue Extract Production from Water-Assisted Lipoaspirate: Methodology for Clinical Use. Biores Open Access. 2016; 5 (1): 269–278. DOI: https://doi.org/10.1089/biores.2016.0030

44. Duan H-F., Wu C-T., Wu D-L., et al. Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Molecular Therapy. 2003; 8 (3): 467–474. DOI: https://doi.org/10.1016/s1525-0016(03)00186-2

45. Gorecka J., Kostiuk V., Fereydooni A., et al. The potential and limitations of induced pluripotent stem cells to achieve wound healing. Stem Cell Research & Therapy. 2019; 10: 87. DOI: https://doi.org/10.1186/s13287-019-1185-1

46. Chambers S.E.J., Pathak V., Pedrini E., et al. Current concepts on endothelial stem cells definition, location, and markers. STEM CELLS Translational Medicine. 2021; 10 (Suppl 2): S54–S61. DOI: https://doi.org/10.1002/sctm.21-0022

47. Salter B., Sehmi R. The role of bone marrow-derived endothelial progenitor cells and angiogenic responses in chronic obstructive pulmonary disease. Journal of Thoracic Disease. 2017; 9 (7): 2168–2177. DOI: https://doi.org/10.21037/jtd.2017.07.56

48. Franz R.W., Parks A., Shah K.J., et al. Use of autologous bone marrow mononuclear cell implantation therapy as a limb salvage procedure in patients with severe peripheral arterial disease. Journal of Vascular Surgery. 2009; 50 (6): 1378–1390. DOI: https://doi.org/10.1016/j.jvs.2009.07.113

49. Chamberlain G., Fox J., Ashton B., Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007; 25 (11): 2739–2749. DOI: https://doi.org/10.1634/stemcells.2007-0197

50. Zuk P.A., Zhu M., Mizuno H., et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Engineering. 2001; 7 (2): 211–228. DOI: https://doi.org/10.1089/107632701300062859

51. Nakagami H., Maeda K., Morishita R., et al. Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005; 25 (12): 2542–2547. DOI: https://doi.org/10.1161/01.ATV.0000190701.92007.6d

52. Magenta A., Florio M.C., Ruggeri M., Furgiuele S. Autologous cell therapy in diabetes‑associated critical limb ischemia: From basic studies to clinical outcomes (Review). International Journal of Molecular Medicine. 2021; 48 (3): 173. DOI: https://doi.org/10.3892/ijmm.2021.5006

53. Lin K., Matsubara Y., Masuda Y., et al. Characterization of adipose tissue-derived cells isolated with the Celution system. Cytotherapy. 2008; 10 (4): 417–426. DOI: https://doi.org/10.1080/14653240801982979

54. Velagapudi P., Turagam M., Kolte D., et al. Intramyocardial autologous CD34+ cell therapy for refractory angina: A meta-analysis of randomized controlled trials. Cardiovascular Revascularization Medicine. 2019; 20 (3): 215–219. DOI: https://doi.org/10.1016/j.carrev.2018.05.018

55. Naseri M.H., Madani H., Tafti A.S.H., et al. COMPARE CPM-RMI Trial: Intramyocardial Transplantation of Autologous Bone Marrow-Derived CD133+ Cells and MNCs during CABG in Patients with Recent MI: A Phase II/III, Multicenter, Placebo-Controlled, Randomized, Double-Blind Clinical Trial. Cell Journal. 2018; 20 (2): 267–277. DOI: https://doi.org/10.22074/cellj.2018.5197

56. Lu D., Jiang Y., Deng W., et al. Long-Term Outcomes of BMMSC Compared with BMMNC for Treatment of Critical Limb Ischemia and Foot Ulcer in Patients with Diabetes. Cell Transplantation. 2019; 28 (5): 645–652. DOI: https://doi.org/10.1177/0963689719835177

57. Heldman A.W., DiFede D.L., Fishman J.E., et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014; 311 (1): 62–73. DOI: https://doi.org/10.1001/jama.2013.282909

58. Franz R.W., Shah K.J., Pin R.H., et al. Autologous bone marrow mononuclear cell implantation therapy is an effective limb salvage strategy for patients with severe peripheral arterial disease. Journal of Vascular Surgery. 2015; 62 (3): 673–680. DOI: https://doi.org/10.1016/j.jvs.2015.02.059

59. Shimizu Y., Kondo K., Hayashida R., et al. Therapeutic angiogenesis for patients with no-option critical limb ischemia by adipose-derived regenerative cells: TACT-ADRC multicenter trial. Angiogenesis. 2022; 25 (4): 535–546. DOI: https://doi.org/10.1007/s10456-022-09844-7

60. Teraa M., Sprengers R.W., Schutgens R.E.G., et al. Effect of repetitive intra-arterial infusion of bone marrow mononuclear cells in patients with no-option limb ischemia: the randomized, double-blind, placebo-controlled Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) trial. Circulation. 2015; 131 (10): 851–860. DOI: https://doi.org/10.1161/CIRCULATIONAHA.114.012913

61. Qayyum A.A., Mathiasen A.B., Helqvist S., et al. Autologous adipose-derived stromal cell treatment for patients with refractory angina (MyStromalCell Trial): 3-years follow-up results. Journal of Translational Medicine. 2019; 17 (1): 360. DOI: https://doi.org/10.1186/s12967-019-2110-1

62. Zhang J., Liu X., Li H., et al. Exosomes/tricalcium phosphate combination scaffolds can enhance bone regeneration by activating the PI3K/Akt signaling pathway. Stem Cell Research & Therapy. 2016; 7 (1): 136. DOI: https://doi.org/10.1186/s13287-016-0391-3

63. Loomans C.J.M., De Koning E.J.P., Staal F.J.T., et al. Endothelial progenitor cell dysfunction in type 1 diabetes: another consequence of oxidative stress? Antioxidants & Redox Signaling. 2005; 7 (11–12): 1468–1475. DOI: https://doi.org/10.1089/ars.2005.7.1468

64. Giannotti G., Doerries C., Mocharla P.S., et al. Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction. Hypertension. 2010; 55 (6): 1389–1397. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.109.141614

65. Puissant B., Barreau C., Bourin P., et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. British Journal of Haematology. 2005; 129 (1): 118–129. DOI: https://doi.org/10.1111/j.1365-2141.2005.05409.x

66. Hare J.M., Traverse J.H., Henry T.D., et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. Journal of the American College of Cardiology. 2009; 54 (24): 2277–2286. DOI: https://doi.org/10.1016/j.jacc.2009.06.055

67. Bartolucci J., Verdugo F.J., González P.L., et al. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). Circulation Research. 2017; 121 (10): 1192–1204. DOI: https://doi.org/10.1161/CIRCRESAHA.117.310712

68. Van Nguyen T-T., Vu N.B., Van Pham P. Mesenchymal Stem Cell Transplantation for Ischemic Diseases: Mechanisms and Challenges. Tissue Engineering and Regenerative Medicine. 2021; 18 (4): 587–611. DOI: https://doi.org/10.1007/s13770-021-00334-3

69. Elshaer S.L., Bahram S.H., Rajashekar P., et al. Modulation of Mesenchymal Stem Cells for Enhanced Therapeutic Utility in Ischemic Vascular Diseases. International Journal of Molecular Sciences. 2021; 23 (1): 249. DOI: https://doi.org/10.3390/ijms23010249

70. Zimta A-A., Baru O., Badea M., et al. The Role of Angiogenesis and Pro-Angiogenic Exosomes in Regenerative Dentistry. International Journal of Molecular Sciences. 2019; 20 (2): 406. DOI: https://doi.org/10.3390/ijms20020406

71. Alonso-Alonso M.L., García-Posadas L., Diebold Y. Extracellular Vesicles from Human Adipose-Derived Mesenchymal Stem Cells: A Review of Common Cargos. Stem Cell Reviews and Reports. 2022; 18 (3): 854–901. DOI: https://doi.org/10.1007/s12015-021-10155-5

72. Ju C., Shen Y., Ma G., et al. Transplantation of Cardiac Mesenchymal Stem Cell-Derived Exosomes Promotes Repair in Ischemic Myocardium. Journal of Cardiovascular Translational Research. 2018; 11 (5): 420–428. DOI: https://doi.org/10.1007/s12265-018-9822-0

73. Gonzalez-King H., García N.A., Ontoria-Oviedo I., et al. Hypoxia Inducible Factor-1α Potentiates Jagged 1-Mediated Angiogenesis by Mesenchymal Stem Cell-Derived Exosomes. 2017; Stem Cells. 35 (7): 1747–1759. DOI: https://doi.org/10.1002/stem.2618

74. Yáñez-Mó M., Siljander PR-M., Andreu Z., et al. Biological properties of extracellular vesicles and their physiological functions. Journal of Extracellular Vesicles. 2015; 4: 27066. DOI: https://doi.org/10.3402/jev.v4.27066

75. Forrester J.S., Libby P. The Inflammation Hypothesis and Its Potential Relevance to Statin Therapy. American Journal of Cardiology. 2007; 99 (5): 732–738. DOI: https://doi.org/10.1016/j.amjcard.2006.09.125

76. Yusoff F.M., Nakashima A., Kawano K., et al. Implantation of Hypoxia-Induced Mesenchymal Stem Cell Advances Therapeutic Angiogenesis. Stem Cells International. 2022; 2022: 1–14. DOI: https://doi.org/10.1155/2022/6795274

77. Ferro F., Spelat R., Shaw G., et al. Survival/Adaptation of Bone Marrow-Derived Mesenchymal Stem Cells After Long-Term Starvation Through Selective Processes. Stem Cells. 2019; 37 (6): 813–827. DOI: https://doi.org/10.1002/stem.2998

78. Brezina R., Schramek S., Kazár J. Selection of chlortetracycline-resistant strain of Coxiella burnetii. Acta Virologica. 1975; 19 (6): 496.

79. Poole-Wilson P.A., Langer G.A. Effect of pH on ionic exchange and function in rat and rabbit myocardium. American Journal of Physiology. 1975; 229 (3): 570–581. DOI: https://doi.org/10.1152/ajplegacy.1975.229.3.570

80. Bian X., Ma K., Zhang C., Fu X. Therapeutic angiogenesis using stem cell-derived extracellular vesicles: an emerging approach for treatment of ischemic diseases. Stem Cell Research & Therapy. 2019; 10: 158. DOI: https://doi.org/10.1186/s13287-019-1276-z

All articles in our journal are distributed under the CC BY-NC-ND 4.0 (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International)

п?? GEOTAR-Media Publishing Group. The use of textual and illustrative content from this publication for the training of any artificial intelligence systems п?? including machine learning models and neural networks п?? is strictly prohibited without the prior written consent of the copyright holder.

CHIEF EDITOR

Yuri V. Belov

Academician of the Russian Academy of Sciences Doctor of Medical Sciences, Professor, President of the Russian Society of Angiologists and Vascular Surgeons

In accordance with the decision of the Presidium of the Russian Society of Angiologists and Vascular Surgeons, the journal "Angiology and Vascular Surgery" will be named after Academician A.V. Pokrovsky starting from No. 2/2022.

Journals of «GEOTAR-Media»